World’s largest society for regulatory professionals increases investment in Europe
An investment of more than 2 million euro over 3 years is planned to launch new events and resources.
The Regulatory Affairs Professionals Society (RAPS) is stepping up its presence in Europe and expanding its European team in response to growing membership demand from those involved with the regulation of healthcare and related products.
In the last 12 months, the largest global organisation for regulatory professionals in the healthcare, medical device, biologic and pharmaceutical sectors has seen its European member base grow by approximately 19% to more than 1,500 members across 29 countries.
RAPS plans to invest more than 2 million euro over 3 years implementing a strategic growth plan in Europe that includes launching new events and resources to serve the needs of regulatory professionals in the region.
RAPS executive director Paul Brooks said: “Europe has a vibrant and progressive healthcare products community and many of our existing regulatory professionals are working here, so increasing our investment in Europe was a natural next step for RAPS.
“Healthcare is a global business, and with more than 15,000 members in over 80 countries, we are well aware of the challenges regulatory professionals face worldwide. Our own research has shown that in Europe more than 65% of professionals in the healthcare product industries have multi-regional or worldwide responsibilities,” said Brooks. “RAPS is committed to understanding the specific needs of European regulatory professionals and supporting our local chapters and networks.”
The investment program includes a substantial increase in staff resources for European members and a series of European events including a RAPS Roadshow: ‘Examining the New European Medical Device Regulations’ on 4 May in Munich and a workshop ‘EU Regulatory Essentials, Medical Device and In Vitro Diagnostics: Transitioning from Current Directives to New Regulations’ on 4 and 5 July in Brussels.
Brooks continued: “In highly regulated environments such as the pharmaceutical and medical device sectors, there is a greater need than ever for regulatory professionals to stay up to date on the latest regulatory developments. In particular, changes to medical device regulations in Europe present a huge challenge to manufacturers and should be high on the industry’s agenda as we move towards the 2020 deadline.”
In addition to in-person events, RAPS will host a four-part virtual programme in May, ‘Understanding the New EU Medical Device and IVD Regulations’ and has produced a helpful ‘interactive guide’ to the new EU Medical Device and IVD Regulations.
As part of its investment in Europe RAPS is also looking to increase awareness of its Regulatory Affairs Certification (RAC). The RAC is the only professional certification specifically for those in the healthcare product regulatory field, testing knowledge and critical thinking relating to the international practice of regulatory affairs. Four RAC credentials are available, including one focused on European regulations. Currently, more than 4,000 individuals around the world are RAC-credentialed.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance